Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Breast 2Plasma cell 1Genitourinary 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1

Interventions

Cyclophosphamide 20fludarabine phosphate 14Peripheral Blood Stem Cell Transplantation 13Dexamethasone 13Cyclosporine 12Whole-Body Irradiation 11fludarabine 10Exercise 10Antilymphocyte Serum 10Melphalan 9Busulfan 9Blood Specimen Collection 9Mycophenolic Acid 8Therapeutics 7Filgrastim 7Bortezomib 7Standard of Care 6Radiotherapy 6Behavior Therapy 6Acupuncture Therapy 6pomalidomide 5Specimen Handling 5Palliative Care 5Methotrexate 5Granulocyte Colony-Stimulating Factor 5Etoposide 5Educational Status 5daratumumab 4Surveys and Questionnaires 4Stem Cell Transplantation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Pharmaceutical Preparations × Plasma cell × Clear all
NCT05889221 2026-04-30

Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

Poitiers University Hospital

Phase NA Active not recruiting
74 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡